• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eurosurv. Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021

tetano

Editor, Senior Moderator
Samuel Alizon[SUP]1[/SUP] , Stéphanie Haim-Boukobza[SUP]2[/SUP] , Vincent Foulongne[SUP]3[/SUP] , Laura Verdurme[SUP]2[/SUP] , Sabine Trombert-Paolantoni[SUP]2[/SUP] , Emmanuel Lecorche[SUP]2[/SUP] , Bénédicte Roquebert[SUP]2[/SUP] , Mircea T. Sofonea

We analysed 9,030 variant-specific RT-PCR tests performed on SARS-CoV-2-positive samples collected in France between 31 May and 21 June 2021. This analysis revealed rapid growth of the Delta variant in three of the 13 metropolitan French regions and estimated a +79% (95% confidence interval: 52–110%) transmission advantage compared with the Alpha variant. The next weeks will prove decisive and the magnitude of the estimated transmission advantages of the Delta variant could represent a major challenge for public health authorities.

full article


https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.28.2100573#html_fulltext
 
Back
Top Bottom